Moderna Stock Falls After Sell Rating from Rothschild
Moderna's stock declined for a second consecutive day as investment firm Rothschild & Co. Redburn issued an unusual 'sell' rating on the company. The downgrade came despite recent positive late-stage trial data for Moderna’s cancer vaccine, developed in partnership with Merck. The analysts at Rothschild cited concerns about whether the market is overestimating the commercial potential of the experimental treatment and questioned if the stock's rally was unjustified given regulatory uncertainties ahead. This rare bearish stance has added pressure to a stock that had been buoyed by recent clinical progress, raising questions among investors. The move highlights growing skepticism in some corners of Wall Street about Moderna’s ability to translate its scientific advancements into sustainable financial returns.
